Describing the Rationale Behind Innate Cell Engager and Cell Therapy Combination Studies, and Sharing Early Clinical Outcomes in Hodgkin Lymphoma

Time: 8:15 am
day: Day Two


  • Outlining the innate and adaptive immune mechanisms to recognize and kill tumor cells, and the avenues for synergistic stimulation (crosstalk)
  • Describing the preclinical data which substantiates synergy between innate cell engager and immune cell functions to enhance in vivo mechanism of action
  • Comparing and contrasting the mode of action and early clinical evidence of AFM13 with NK cell therapies vs. checkpoint inhibitor and in monotherapy, and where promise lies to elicit maximum clinical benefit